Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease.
Thorax
; 62(11): 1013-4, 2007 Nov.
Article
en En
| MEDLINE
| ID: mdl-17965080
ABSTRACT
The use of anti-tumour necrosis factor (TNF) agents has expanded significantly over the past few years, particularly for rheumatological diseases and Crohn's disease. A number of associated opportunistic infections have been observed as a result of suppression of T cell-mediated immunity, the most frequent being tuberculosis. We report the first case of pulmonary actinomycosis in a patient receiving regular infusions of infliximab, an anti-TNF agent, for Crohn's disease.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Infecciones Oportunistas
/
Fármacos Gastrointestinales
/
Actinomicosis
/
Enfermedad de Crohn
/
Enfermedades Pulmonares
/
Anticuerpos Monoclonales
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Thorax
Año:
2007
Tipo del documento:
Article
País de afiliación:
Canadá